Ashland Global Hlds

Ashland, Inc. engages in the provision of architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical. It operates through the following segments: Life Sciences, Personal Care, Special Additives, and Intermediates. The company was founded in 1924 and is headquartered in Wilmington, DE.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Ashland Global Hlds reports solid Q1 performance amidst regional challenges

Ashland Global Hlds' Q1 earnings call highlighted a mix of strong performance, challenges in certain regions, and opportunities for growth through strategic initiatives. The company's focus on enhancing shareholder value, addressing market uncertainties, and driving innovation positions it for future success.

Ashland Global Hlds faces Q2 challenges, eyes pharma growth

Ashland Global Hlds faced challenges in Q2 2023 from global uncertainties and destocking, impacting margins and earnings, while showing strength in the pharma and Life Sciences segments.
The company's strategic focus on M&A in growth areas and ending destocking actions in key segments present opportunities for revenue growth and value creation.
Despite challenges, Ashland's performance reflects resilience and strategic decision-making, with a positive outlook for cash flow improvement and long-term growth.
Investors should monitor the company's progress in addressing challenges, leveraging strengths, and capitalizing on opportunities to drive sustainable financial performance.

Ashland Global Hlds faces destocking challenges but emphasizes resilience and growth

Ashland Global Hlds faced challenges from customer destocking, leading to a decline in sales and adjusted EBITDA, but demonstrated resilience and strength in managing mix improvements and margins.
The company remains focused on innovation, growth opportunities, and market confidence, with investments in core assets and new technologies continuing despite market challenges.
Opportunities lie in new product initiatives, global expansion, and capacity additions in key technologies, positioning Ashland Global Hlds for future growth and success.
Despite short-term challenges, Ashland Global Hlds maintains a strategic outlook, emphasizing long-term strategies, market confidence, and a commitment to driving growth through innovation.

Ashland Global Hlds faces challenges but targets growth opportunities

Ashland Global Hlds faced challenges in Q4 and anticipates uncertainties in 2024 but remains focused on long-term growth opportunities.
The company is optimizing its portfolio, targeting new growth drivers, and managing costs effectively to navigate current market conditions.
Despite near-term challenges, Ashland is resilient and committed to maximizing upside potential while minimizing downside risks.
Management's emphasis on proactive inventory control, cost management, and strategic priorities underscores their commitment to long-term success.

Ashland Global Hlds reports mixed Q1 results, focuses on long-term growth

Ashland Global Hlds reported mixed Q1 results with sales decline and EBITDA decrease, focusing on long-term growth strategies and shareholder value creation.
Challenges include lower demand in key units, compensation adjustments, market dynamics, and cost management considerations, while opportunities lie in M&A, innovation, and market expansion.
Stability in certain business segments and strategic initiatives to optimize operations provide a foundation for future growth and profitability amidst current challenges.
Overall, Ashland's performance reflects a balancing act between short-term setbacks and long-term strategic positioning for sustainable growth and market competitiveness.

Ashland Global Hlds beats Q2 expectations, eyes growth opportunities

Ashland Global Hlds demonstrated resilience in Q2 2024, exceeding EBITDA outlook and focusing on strategic growth.
Despite challenges in pricing and market dynamics, the company maintains a strong financial position and growth focus.
Opportunities lie in innovation, segment growth, and EBITDA normalization above 2021 levels.
The company's performance reflects a balance of challenges, strengths, and a proactive approach to future growth.

Ashland reports solid Q4 results, eyes global growth opportunities

Ashland Global Hlds (ASH) delivered a resilient performance in Q4 2024, with sales and adjusted EBITDA showing positive growth trends.
Strategic priorities for fiscal year 2025 aim to address challenges, capitalize on opportunities, and drive profitable growth for the company.
Despite near-term uncertainties, Ashland remains optimistic about its long-term prospects and ability to navigate evolving market conditions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ashland, Inc. is an additives and specialty ingredients company, which engages in the provision of architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical products. It operates through the following segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. The Life Sciences segment is involved in pharmaceuticals, nutrition, nutraceuticals, agricultural chemicals, diagnostic films, and fine chemicals. The Personal Care segment consists of biofunctionals, microbial protectants, skin care, sun care, oral care, hair care, and household solutions. The Specialty Additives segment focuses on rheology and performance-enhancing additives serving the architectural coatings, construction, energy, automotive, and various industrial markets. The Intermediates segment refers to production of 1,4 butanediol and related derivatives, including n-methylpyrrolidone. The company was founded in 1924 and is headquartered in Wilmington, DE.

WILMINGTON, Del., Nov. 14, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on December 15, 2024, to stockholders of record at the close of business on December 1, 2024.

Ashland board authorizes quarterly dividend

ASH sees higher sales volumes in Personal Care, Specialty Additives and Intermediates segments in Q4.

Ashland's Earnings Miss in Q4, Revenues Surpass Estimates

Ashland Inc. (NYSE:ASH ) Q4 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants William Whitaker - VP, Finance and Director, IR Guillermo Novo - Chair and CEO Kevin Willis - SVP and CFO Alessandra Faccin - SVP and GM, Life Sciences and Intermediates Jim Minicucci - SVP and GM, Personal Care Dago Caceres - SVP and GM, Specialty Additives Conference Call Participants Michael Sison - Wells Fargo James Cannon - UBS John Roberts - Mizuho Mike Harrison - Seaport Research Partners Operator Thank you for standing by. My name is Hermione and I will be your conference operator today.

Ashland Inc. (ASH) Q4 2024 Earnings Call Transcript

Celanese

Mativ Inc

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.

Top 3 Materials Stocks That Are Preparing To Pump In Q4

WILMINGTON, Del., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) will host a strategy update event for analysts and investors on Tuesday, December 10, 2024, in New York City. The company will provide an in-depth review of Ashland's strategic priorities, key initiatives and financial objectives while emphasizing a proactive approach to market uncertainty in fiscal year 2025.

Ashland to host live 2024 strategy update event for analysts and investors

While the top- and bottom-line numbers for Ashland (ASH) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ashland (ASH) Reports Q4 Earnings: What Key Metrics Have to Say

Ashland (ASH) came out with quarterly earnings of $1.26 per share, missing the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $0.41 per share a year ago.

Ashland (ASH) Q4 Earnings Lag Estimates

Evaluate the expected performance of Ashland (ASH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Unveiling Ashland (ASH) Q4 Outlook: Wall Street Estimates for Key Metrics

Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ashland (ASH) Reports Next Week: Wall Street Expects Earnings Growth

WILMINGTON, Del., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its fourth-quarter fiscal 2024 earnings release at approximately 5 p.m. ET on Wednesday, November 6, 2024. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Thursday, November 7. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com .

Ashland sets date for fourth-quarter fiscal 2024 earnings release and conference call webcast

NEW YORK--(BUSINESS WIRE)--D.A. Davidson & Co. announced today that it served as exclusive financial advisor to Turnspire Capital Partners LLC (“Turnspire”) on an asset-backed credit facility to finance Turnspire's acquisition of Pharmachem Innovations, LLC (“Pharmachem” or the “Company”), the former nutraceuticals business of Ashland Inc. (NYSE: ASH). “We appreciate the D.A. Davidson team's efforts in securing an attractive financing package for a complicated carve-out transaction, which e.

D.A. Davidson Acts as Exclusive Financial Advisor to Turnspire Capital Partners for Debt Financing in Support of Turnspire's Acquisition of Pharmachem

ASH's technology enables agricultural retailers to increase crop yield, facilitating organic growth.

Ashland Boosts the Application of Super Wetting Technology

ASH's nutraceuticals business provides nutrition product producers with a diverse selection of active ingredients and formulation aids.

Ashland Wraps Up Nutraceuticals Business Sale to Turnspire Affiliate

WILMINGTON, Del., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced it has completed the sale of its nutraceuticals business to an affiliate of Turnspire Capital Partners LLC (“Turnspire”) effective August 30, 2024. The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.

Ashland completes sale of nutraceuticals business

KEARNY, N.J.--(BUSINESS WIRE)--Pharmachem Innovations, LLC (“Pharmachem” or the “Company”), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE: ASH) by Turnspire Capital Partners LLC (“Turnspire”). Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuti.

Pharmachem Innovations Launches as a Leading Independent Provider of Nutraceuticals Products and Solutions

NEW YORK--(BUSINESS WIRE)--Turnspire Capital Partners LLC (“Turnspire”) announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC (“Pharmachem” or the “Company”), the former nutraceuticals business of Ashland Inc. (NYSE: ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition.

Turnspire Capital Partners Completes Acquisition of Pharmachem from Ashland

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Ashland (ASH) is a Strong Value Stock

Investors with an interest in Chemical - Specialty stocks have likely encountered both Ashland (ASH) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?

ASH vs. NVZMY: Which Stock Should Value Investors Buy Now?

Ashland Inc. (NYSE:ASH ) Q3 2024 Earnings Conference Call August 7, 2024 10:00 AM ET Company Participants William Whitaker - Vice President-Finance and Director-Investor Relations Guillermo Novo - Chair of the Board and Chief Executive Officer Kevin Willis - Senior Vice President and Chief Financial Officer Conference Call Participants Christopher Parkinson - Wolfe Research John McNulty - BMO Capital Markets David Begleiter - Deutsche Bank Michael Sison - Wells Fargo Mike Harrison - Seaport Research Partners Jeff Zekauskas - JPMorgan John Roberts - Mizuho Joshua Spector - UBS Operator Good day and thank you for standing by. Welcome to the Ashland Inc. Third Quarter 2024 Earnings Conference Call.

Ashland Inc. (ASH) Q3 2024 Earnings Call Transcript

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Ashland (ASH) is a Top Value Stock for the Long-Term

Ashland's (ASH) Q3 sales are adversely impacted by reduced Life Sciences volumes and weaker pricing.

Ashland's (ASH) Earnings Beat Estimates in Q3, Sales Lag

Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Ashland (ASH) Q3 Earnings

Ashland (ASH) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $1.23 per share a year ago.

Ashland (ASH) Surpasses Q3 Earnings Estimates

WILMINGTON, Del., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced financial results1 for the third quarter of fiscal year 2024, which ended June 30, 2024, and issued its outlook for fourth quarter and full-year fiscal 2024. The global additives and specialty ingredients company holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coatings.

Ashland reports financial results1 for third quarter fiscal 2024, issues outlook for fourth quarter and full-year fiscal 2024

Here is how Ashland (ASH) and Fortuna Mining (FSM) have performed compared to their sector so far this year.

News for Ashland Global Hlds Stock (ASH)